Tuomas T. Rissanen

VEGF-D Is the Strongest Angiogenic and Lymphangiogenic Effector Among VEGFs Delivered Into Skeletal Muscle via Adenoviruses

Tuomas T. Rissanen, Johanna E. Markkanen, Marcin Gruchała et al. · Circulation Research · 2003 · 439 citations

VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis

Fan Zhang, Zhongshu Tang, Xu Hou et al. · Proceedings of the National Academy of Sciences · 2009 · 302 citations · Full text

Retinal Neovascularization, Immunology, Pathology +20

Drug-coated balloon for treatment of de-novo coronary artery lesions in patients with high bleeding risk (DEBUT): a single-blind, randomised, non-inferiority trial

Tuomas T. Rissanen, Sanna Uskela, Jaakko Eränen et al. · The Lancet · 2019 · 225 citations

Percutaneous Coronary Intervention, Drug-coated Balloon, Cardiovascular Disease +9

Vascular Endothelial Growth Factor-B Induces Myocardium-Specific Angiogenesis and Arteriogenesis via Vascular Endothelial Growth Factor Receptor-1– and Neuropilin Receptor-1–Dependent Mechanisms

Johanna Lähteenvuo, Markku Lähteenvuo, Antti Kivelä et al. · Circulation · 2009 · 195 citations

Adenoviral Catheter-Mediated Intramyocardial Gene Transfer Using the Mature Form of Vascular Endothelial Growth Factor-D Induces Transmural Angiogenesis in Porcine Heart

Juha Rutanen, Tuomas T. Rissanen, Johanna E. Markkanen et al. · Circulation · 2004 · 189 citations · Full text